This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Currently Amended) A near infrared fluorescent contrast agent comprising a pharmaceutically acceptable injectable carrier for diagnostic imaging and a compound of the following formula or a pharmaceutically acceptable salt thereof:

wherein

 $R^1$ ,  $R^2$ ,  $R^7$ , and  $R^8$  independently represent a substituted or unsubstituted  $C_1$ - $C_{10}$  alkyl group or a substituted or unsubstituted aryl group; [[ $_7$ ]] or

R<sup>1</sup> and R<sup>2</sup> and/or R<sup>7</sup> and R<sup>8</sup> bind to each other to form a ring;

 $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$  and  $R^{12}$  independently represent a hydrogen atom, a substituted or unsubstituted  $C_1$ - $C_6$  alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a halogen atom, cyano group, carboxyl group, or sulfo group; [[ $_7$ ]] or

 $\underline{\text{two of}}\ R^3, R^4, R^5, R^6, R^9, R^{10}, R^{11}$  and  $R^{12}$  bind to each other to form a ring;

 $X^2$  represents a substituted or unsubstituted  $C_1$ - $C_{15}$  alkyl group or a substituted or unsubstituted aryl group; and

X<sup>1</sup> is a group represented by the following formula

wherein

X<sup>1</sup> and X<sup>2</sup> in total have 2 or 4 carboxyl groups;

 $Y^1$  and  $Y^2$  independently represent a substituted or unsubstituted divalent linking group; and

X<sup>4</sup> and X<sup>2</sup> in total have 2 or 4 carboxyl groups;

m<sup>1</sup> represents 0 or 1;

m<sup>2</sup> represents 0 or 1;

m<sup>3</sup> represents 0 or 1;

 $L^1$ ,  $L^2$ ,  $L^3$ ,  $L^4$ ,  $L^5$ ,  $L^6$ , and  $L^7$  independently represent a substituted or unsubstituted methine group, provided that when two or more of the methine groups have substituents, the substituents bind to each other to form a ring:

M represents a hydrogen atom, a metal, or a quaternary ammonium salt; and

n represents an integer of 1 to 7 necessary for neutralizing charge

and a pharmaceutically acceptable carrier for diagnostic imaging.

- 2. (Original) The near infrared fluorescent contrast agent according to claim 1, wherein each of  $m^1$ ,  $m^2$ , and  $m^3$  is 1.
  - 3. (Canceled)
- 4. (Previously Presented) The near infrared fluorescent contrast agent according to claim 1, wherein  $X^1$  and  $X^2$  independently represent a group represented by the following formula:

wherein Y<sup>1</sup> and Y<sup>2</sup> independently represent a substituted or unsubstituted divalent bond.

- 5. (Original) The near infrared fluorescent contrast agent according to Claim 1, wherein at least one of  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
  - 6. (Canceled)

- 7. (Canceled)
- 8. (Currently Amended) The near infrared fluorescent contrast agent according to Claim 3.

wherein  $Y_1$  represents -(CH<sub>2</sub>)<sub>p</sub>CONH-, wherein p represents an integer of 1 to 4 and  $Y_2$  represents -(CH<sub>2</sub>)- or (CH<sub>2</sub>)<sub>2</sub>-.

- 9. (Cancelled)
- 10. (Cancelled)
- 11. (Currently Amended) A method of fluorescence imaging, comprising which comprises the steps introducing the near infrared fluorescent contrast agent according to Claim 1 into a living body, exposing said body to an excitation light, and detecting near infrared fluorescence from the contrast agent.
- 12. (Currently Amended) A <u>The</u> method of claim 11, <u>which is</u> for tumor imaging.
- 13. (Currently Amended) A <u>The</u> method of claim 11, which is for angiography.
- 14. (New) The near infrared fluorescent contrast agent according to claim 1, wherein the pharmaceutically acceptable injectable carrier for diagnostic imaging is injectable distilled water.
- 15. (New) The near infrared fluorescent contrast agent according to claim 1, wherein the pharmaceutically acceptable injectable carrier for diagnostic imaging is physiological saline.

- 16. (New) The near infrared fluorescent contrast agent according to claim 1, wherein the pharmaceutically acceptable injectable carrier for diagnostic imaging is Ringer's solution.
- 17. (New) The near infrared fluorescent contrast agent according to Claim 5, wherein at least one of  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  is a substituted or unsubstituted aryl group.
- 18. (New) The near infrared fluorescent contrast agent according to Claim 5, wherein at least one of  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  is a substituted or unsubstituted heteroaryl group.